Prosetin Capsule 20mg (Fluoxetine Hydrochloride)

Adult dosage

Adults 1. Depression 1) Initial treatment: The initial dose is 20mg of fluoxetine hydrochloride orally once daily in the morning. In controlled clinical trials, doses of 20～80mg per day were administered. If no improvement is observed, an increase in dose may be considered after several weeks. Doses above 20mg per day should be administered twice daily (morning and noon), and the maximum dose of 80mg per day should not be exceeded. The onset of a sufficient antidepressant effect may be delayed until 4 weeks or longer of treatment. 2) Maintenance/continuation/extended treatment: There are no definitive data on the duration of treatment with this medicine; however, psychopharmacologists recognize that acute episodes of depression require medication treatment for several months or longer. It is not known whether the amount of antidepressant needed to relieve symptoms is the same as that needed to maintain or sustain stability. 2. Bulimia nervosa Administer 60mg of this medicine per day. The daily dose should not exceed 80mg. Measure electrolyte levels before starting treatment. 3. Obsessive-compulsive disorder Administer 20～60mg of this medicine per day. The daily dose should not exceed 80mg. 4. Premenstrual dysphoric disorder Administer 20mg of this medicine per day. Reassess the need for continued treatment after 6 months of therapy. Patients with renal and/or hepatic impairment, patients receiving multiple medicines, older adults, and patients with concomitant illnesses: Administer a low dose or reduce the frequency of administration. Adjust the dose as appropriate according to age and symptoms. Switching from MAO inhibitors used to treat psychiatric disorders When stopping an MAO inhibitor used to treat a psychiatric disorder and starting treatment with this medicine, allow an interval of at least 14 days. Conversely, when starting an MAO inhibitor to treat a psychiatric disorder, at least 5 weeks must have elapsed after discontinuing this medicine. Other MAO inhibitors such as linezolid or methylene blue Patients receiving linezolid or intravenous methylene blue preparations should not start treatment with this medicine because of the increased risk of serotonin syndrome. For patients requiring more urgent treatment of a psychiatric condition, including hospitalization and other interventions, consider treatment. It may be necessary to urgently administer linezolid or intravenous methylene blue preparations to a patient already receiving this medicine. If there is no alternative to linezolid or intravenous methylene blue preparations and the benefits of treatment with linezolid or intravenous methylene blue preparations are judged to outweigh the risk of serotonin syndrome in a particular patient, discontinue this medicine immediately and administer linezolid or intravenous methylene blue preparations. Monitor the patient for symptoms of serotonin syndrome for 5 weeks after administration of linezolid or intravenous methylene blue preparations, or for 24 hours after the last dose, whichever occurs first. Treatment with this medicine may be restarted 24 hours after the last dose of linezolid or intravenous methylene blue preparations. The risks associated with administration of methylene blue by non-intravenous routes (oral tablets or local injection) or intravenous administration of this medicine at a dose of 1mg/kg or less are unclear. Nevertheless, clinicians should be aware of the possibility of emergency symptoms of serotonin syndrome with these uses.

This medication is an antidepressant used to treat psychiatric disorders such as major depression. There is an increased risk of suicidal thoughts or behaviors when this medication is administered, particularly in children, adolescents, and young adults aged 18 to 24, thus it is crucial to consult a doctor before administration and make careful decisions. This medication should not be given to patients who are hypersensitive to this drug or its ingredients, those with severe renal impairment, and those currently taking MAO inhibitors. Patients with a history of seizures should be cautious when using this medication and should stop its use immediately if seizures occur or frequency increases. This medication can affect the heart, so an electrocardiogram is recommended for patients with heart diseases or those at risk of QT interval prolongation before administration, and should be stopped immediately if abnormal signs appear during use. Patients with impaired liver or kidney function should adjust the dosage of this medication, and diabetic patients should regularly monitor blood glucose levels as there may be changes in glucose control. This medication can cause pupil dilation, so it must be used cautiously in patients with increased intraocular pressure or risk of acute angle-closure glaucoma. Common side effects during treatment may include headaches, nausea, insomnia, fatigue, and diarrhea, while rare but serious allergic reactions or skin rashes can occur. During the initial treatment phase or when adjusting the dose, abnormal behavioral changes such as suicidal thoughts and actions, aggression, and anxiety may appear; thus, patients and their caregivers should closely monitor and immediately report any abnormal symptoms to their doctor. There is a risk of a serious side effect known as serotonin syndrome when used with other serotonin-active drugs; therefore, it must be taken under a doctor's guidance for co-administration. Pregnant or breastfeeding women should consult healthcare professionals before using this medication, as it may affect the fetus or newborn. This medication has not established safety and efficacy in children and adolescents, so it is preferable to avoid its use in this population. In the case of overdose, symptoms such as nausea, vomiting, seizures, and heart anomalies may occur; immediate medical attention is required. When discontinuing, it is important not to stop suddenly but to gradually taper off according to a doctor's instructions to prevent withdrawal symptoms. Alcohol consumption during treatment is not recommended, and caution should be exercised when driving vehicles or operating hazardous machinery. This medication must be kept out of reach of children, and it is advised not to transfer it to another container.

Headache, nausea, insomnia, fatigue, diarrhea, anaphylactic reaction, serum sickness, abnormal secretion of antidiuretic hormone, decreased appetite, hyponatremia, anxiety, irritability, restlessness, tension, decreased libido, sleep disorders, abnormal dreams, depersonalization, elevated mood, euphoric mood, abnormal thoughts, abnormal libido, bruxism, hypomania, mania, hallucinations, agitation, panic attacks, suicidal impulses and behavior, confusion, attention disorders, dizziness, taste abnormalities, hypersomnolence, drowsiness, tremor, psychomotor agitation, movement disorders, ataxia, balance disorders, tonic-clonic muscle spasms, seizures, inability to sit still, Buccglosal syndrome, serotonin syndrome, memory disorders, blurred vision, mydriasis, palpitations, ventricular arrhythmia, QT prolongation, flushing, hypotension, vasculitis, vasodilation, yawning, dyspnea, pharyngitis, pulmonary-related events, epistaxis, vomiting, dyspepsia, dry mouth, dysphagia, esophageal pain, gastrointestinal bleeding, specific hepatitis, rash, urticaria, pruritus, hyperhidrosis, increased tendency for bruising, diaphoresis, angioedema, petechiae, photosensitivity, purpura, erythema multiforme, arthralgia, muscle cramp, myalgia, frequent urination, dysuria, urinary retention, urination disorders, gynecological bleeding, erectile dysfunction, ejaculation disorder, sexual dysfunction, galactorrhea, hyperprolactinemia, priapism, anxious mood, chills, lethargy, abnormal mood, feeling cold, feeling hot, mucosal bleeding, weight loss, abnormal liver function tests, fractures, dizziness, sensory disturbances, sleep disturbances, asthenia, agitation, anxiety, tremor, headache, anaphylactoid reaction, gradual systemic reaction, severe skin, kidney, liver, or pulmonary-related reactions, hyponatremia, platelet function changes, abnormal bleeding, aplastic anemia, atrial fibrillation, cataracts, cerebrovascular accident, cholestatic jaundice, movement disorder, eosinophilic pneumonia, epithelial necrosis, erythema multiforme, nodular erythema, exfoliative dermatitis, gynecomastia, cardiac arrest, liver failure, necrosis, hyperprolactinemia, hypoglycemia, immune-related hemolytic anemia, renal failure, movement disorder, optic neuritis, pancreatitis, pancytopenia, pulmonary embolism, pulmonary hypertension, QT prolongation, Stevens-Johnson syndrome, thrombocytopenia, thrombocytopenic purpura, ventricular tachycardia, vaginal bleeding, aggressive behavior

This medication should be stored in a tightly closed container to protect it from air and moisture. It is best stored at room temperature between 1 and 30 degrees Celsius.

Appearance

A hard capsule with a green upper part and a light yellow lower part filled with a white to off-white powder.

Package unit

30 capsules/bottle, 300 capsules/bottle